Linzagolix: First Approval.

Article Details

Citation
Copy to clipboard

Keam SJ

Linzagolix: First Approval.

Drugs. 2022 Aug;82(12):1317-1325. doi: 10.1007/s40265-022-01753-9.

PubMed ID
35997940 [ View in PubMed
]
Abstract

Linzagolix (Yselty((R))) is an orally administered, selective, non-peptide small molecule gonadotrophin releasing hormone (GnRH) receptor antagonist that is being developed by Kissei Pharmaceutical for the treatment of uterine fibroids and endometriosis in women of reproductive age. Linzagolix binds to and blocks the GnRH receptor in the pituitary gland, modulating the hypothalamic pituitary-gonadal axis and dose-dependently reducing serum luteinising hormone and follicle-stimulating hormone production and serum estradiol levels. In June 2022, linzagolix was approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age in the EU. Linzagolix is under regulatory review the USA for this indication and is in phase 3 clinical development in the treatment of pain associated with endometriosis. This article summarizes the milestones in the development of linzagolix leading to this first approval for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

DrugBank Data that Cites this Article

Drugs